Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Dual roles of apolipoprotein CI in the formation of atherogenic remnants.

Björkegren J.

Curr Atheroscler Rep. 2006 Jan;8(1):1-2. No abstract available.

PMID:
16455004
2.
3.

Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes.

Masson D, Pais de Barros JP, Zak Z, Gautier T, Le Guern N, Assem M, Chisholm JW, Paterniti JR Jr, Lagrost L.

J Lipid Res. 2006 Feb;47(2):356-65. Epub 2005 Nov 10.

4.

Glycosylation of lipoproteins: chemistry and biological implications.

Flückiger R.

Monogr Atheroscler. 1985;13:53-62. Review. No abstract available.

PMID:
3911059
5.

Human apolipoprotein C-I: concentration in blood serum and lipoproteins.

Polz E, Kotite L, Havel RJ, Kane JP, Sata T.

Biochem Med. 1980 Dec;24(3):229-37. No abstract available.

PMID:
7283981
6.

Postprandial enrichment of remnant lipoproteins with apoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis.

Björkegren J, Silveira A, Boquist S, Tang R, Karpe F, Bond MG, de Faire U, Hamsten A.

Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1470-4.

PMID:
12231568
7.
8.

Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins.

Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G.

Biochem Soc Trans. 2003 Oct;31(Pt 5):1070-4. Review.

PMID:
14505482
9.

Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.

Dergunov AD, Smirnova EA, Merched A, Visvikis S, Siest G, Yakushkin VV, Tsibulsky V.

Biochim Biophys Acta. 2000 Feb 24;1484(1):29-40.

PMID:
10685028
10.

Role of arterial lipoproteins in the formation of the fibrous plaque.

Hollander W.

Adv Exp Med Biol. 1977;82:793-9. No abstract available.

PMID:
200107
11.

Metabolism of apolipoprotein C-I in normolipoproteinemic human subjects.

Malmendier CL, Lontie JF, Grutman GA, Delcroix C.

Atherosclerosis. 1986 Nov;62(2):167-72.

PMID:
3099803
12.

Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.

Cohn JS, Batal R, Tremblay M, Jacques H, Veilleux L, Rodriguez C, Mamer O, Davignon J.

J Lipid Res. 2003 Oct;44(10):1976-83. Epub 2003 Jul 16.

13.

Apolipoprotein C-I reduces cholesteryl esters selective uptake from LDL and HDL by binding to HepG2 cells and lipoproteins.

Krasteva V, Brodeur MR, Tremblay FL, Falstrault L, Brissette L.

Biochim Biophys Acta. 2010 Jan;1801(1):42-8. doi: 10.1016/j.bbalip.2009.09.001. Epub 2009 Sep 15.

PMID:
19761869
14.

Activation of plasma lysolecithin acyltransferase reaction by apolipoproteins A-I, C-I and E.

Liu M, Subbaiah PV.

Biochim Biophys Acta. 1993 Jun 12;1168(2):144-52.

PMID:
8504148
15.

[Role of HDL lipoproteins in atherosclerosis].

Machura B, Kryczka W.

Pol Tyg Lek. 1977 Sep 19;32(38):1487-9. Polish. No abstract available.

PMID:
198755
16.

Remnant lipoproteins as therapeutic targets.

Havel RJ.

Curr Opin Lipidol. 2000 Dec;11(6):615-20. Review.

PMID:
11086335
17.

Metabolism of apolipoprotein C-III in normolipemic human subjects.

Malmendier CL, Lontie JF, Grutman GA, Delcroix C.

Atherosclerosis. 1988 Jan;69(1):51-9.

PMID:
3355607
18.

Apolipoprotein C-II modifications associated with an infusion of artificial lipid particles.

Iriyama K, Nishiwaki H, Terashima H, Tonouchi H, Miki C, Suzuki H, Carpentier YA.

JPEN J Parenter Enteral Nutr. 1988 Jan-Feb;12(1):60-2.

PMID:
3125357
19.

[Metabolism of atherogenic lipoproteins].

Beucler I, Turpin G.

Ann Med Interne (Paris). 2001 Apr;152(3):158-61. Review. French.

PMID:
11431574

Supplemental Content

Support Center